ACTA1 and breast carcinoma: In conclusion, the high expression of α-SMA, PDPN, PDGFR-β in CAFs led to unfavorable clinical outcomes in breast cancer patients, implicating that all these biomarkers could have potential values in the treatment and prognostic evaluation of breast cancer patients.